## UNITED STATES PATENT AN

Applicants: Application No.: Date Filed:

Laurence Goux-Capes Unknown 12/03/2002 PCT/EP2003/050906

Group Art Unit: Unknown Examiner: Unknown Batch No.: Unknown Intl. Filing Date: 11/27/2003

Intl. Appl. No.: Title:

LINKAGE OF NANOMORPHIC CARBON TO A NUCLEIC ACID

## INFORMATION DISCLOSURE STATEMENT (IDS)

Assistant Commiss	sioner For Patents
Washington, D.C.	20231

SIR:				§§1.97 and 1.98, the references listed submitted herewith for consideration
		tes Patent and Trademark		
I.	COPIES a.⊠	A legible copy of (i) eac		ach publication or that portion which portion which caused it to be listed, is
	b. <u></u>	Any patents, publications enclosed herewith were		listed on PTO/SB/08 which are not to the PTO in one of the following date under 35 U.S.C. §120:
		U.S. Serial Number		U.S. Filing Date
II.	CONCI: a. ⊠ b. □ c. □	Except as may be indicat information are in the Eng A concise explanation of is not in the English langu	glish language (concise explanation the relevance of all patents, public	l of the patents, publications or other not required). ations or other information listed that
ш. 🗌	The Exarelated	to the present application	ollowing co-pending application(s)	contain(s) subject matter that may be ications to the Examiner's attention, J.S.C. §122.
	Serial N	<u>o.</u>	Filing Date	Art Unit
			<u>FEES</u>	
IV. 🛛	THIS III a.⊠ b.□ c.□	within three months of the application under § 1.53(c) within three months of international application (	1) (37 C.F.R. §1.97(b)(1)). No fee of the date of entry of the national (37 C.F.R. §1.97(b)(2)). No fee or s	on other than a continued prosecution or statement is required.  stage as set forth in § 1.491 in an
	a 🗀	hafara tha mailing data	of a first Office Action after th	a filing of a request for continued

		<del></del>
v. 🖂	THIS II	OS IS BEING FILED UNDER 37 C.F.R. §1.97(b): (check one box)
_	a. 🖂	within three months of the filing date of a national application other than a continued prosecution
		application under § 1.53(d) (37 C.F.R. §1.97(b)(1)). No fee or statement is required.
	b. 🔲	within three months of the date of entry of the national stage as set forth in § 1.491 in an
		international application (37 C.F.R. §1.97(b)(2)). No fee or statement is required.
	c. 🗌	before the mailing date of a first Office Action on the merits (37 C.F.R. §1.97(b)(3)). No fee or statement is required.
	d. 🗌	before the mailing date of a first Office Action after the filing of a request for continued examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.
v. 🔲	THIS II	OS IS BEING FILED UNDER 37 C.F.R. §1.97(c): (check one box)

before the mailing date of any of a Final Office Action under 37 C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (See 37 C.F.R. §1.97(c)).

VI. 🗌		See OS IS BEI efore payr a statem	nent; therefore, charge deposit accuratement below. No fee is required to the interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the issue fee and is accompanded and interest of the inte	d. 97(d): UC17 Re anied by the following vided below; and	c'd PCM 53724 Juli	2005
VII. 🔯		ersigned each iter Office ir no item Office in after ma individu statemer some of foreign I containe foreign a informat the IDS applicati inquiry,	NDER 37 C.F.R. §1.97(e) (check of hereby states that more information contained in the III in a counterpart foreign application in a counterpart foreign application, as a counterpart foreign application, as a counterpart foreign application, as the interpart foreign application, as a counterpart foreign application, as a counterpart foreign application, as the items of information contained and in the IDS was cited in a communication not more than three most ion, the undersigned hereby states was cited in a communication for item of information contained in .56(c) more than three months prioriging in the IDS was cited in a communication for item of information contained in .56(c) more than three months prioriging in the IDS was cited in a communication for item of information contained in .56(c) more than three months prioriging in the IDS was cited in a communication for the knowledge of the properties of the proper	DS was cited in a common more than three more so was cited in a common and to knowledge of a finformation contains of more than three more than three more than three more than the IDS were con, the undersigned structure of the filing that no item of this reform a foreign Patent person signing the stantal the IDS was known that the IDS was known the IDS was known that the IDS was known the IDS was known the IDS was known the IDS was	nmunication from a foreign Patent onths prior to the filing of IDS; or munication from a foreign Patent of the person signing the statement and in the IDS was known to any nonths prior to the filing of this cited in a communication from a ates that each item of information ign Patent Office in a counterpart of this IDS. As to the remaining maining information contained in the Office in a counterpart foreign atement after making reasonable to any individual designated in 37	BEST AVAILABLE COPY
	The abore statute either si	Please of fee(s). If Applie Commis Two Coperer referency prior ngly or in	in the amount of is enclosed in the amount of is enclosed any additional assioner is hereby authorized to credipies of this paper are attached for Dences are being cited only in the in art or contain matter which anticinal a combination, to a person of ordinas any questions concerning this II	fees, or if any overpay t or debit Deposit Acceposit Account charge terests of candor and pates the invention of many skill in the art.	0.00 for the above-indicated yment has been made, the count 502117 es and debits.  Without any admission that they or which would render the same	COPY
			S has been filed under the wrong runder if necessary) and charge the appro	Respectfully submitt Laurence Goux-Cap	Account No. 502117. ted,	
	ROLA, IN er Numbe			Daniel K. Nichols Attorney for Applica Reg. No. 29,420		
Enclosu	res:		Information Disclosure Statement by Applicant References Foreign Search Report Other:	Telephone No.: (84 Fax No.: (847) 576-3		

10/537411 JC17 APCT/PTO 02 JUN 2005 -

					Complete if Known
l	INFORMATION D	ISCLOSUF	E	Application Number	
Si	STATEMENT BY APPLICANT		Filing Date	12/03/2002	
				First Named Inventor	LAURENCE GOUX-CAPES
				Group Art Unit	N/A
(use as many	sheets as necessary)			Examiner Name	N/A
Sheet	1	of	2	Attorney Docket Number	CML00690CR
					<u> </u>

				. U. S. PATENT DOCUMENTS		
Examiner Initials*	Cite No. 1	U.S. Pate Number	ent Document Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		<u> </u>			1	
		<u> </u>				
		-				
					<del>                                     </del>	
		<del> </del>				
		<del> </del>				

Examiner Cite		Foreign Patent Document			Name of Patentee or	Date of	Pages, Columns, Lines,	T <sup>6</sup>	
Initials* No. 1	No. 1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Cod (if know		Applicant of Cited Document	Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	
			WO01/6668	7		Genometrix	09/13/2001		
			WO02/0950	99		Univ. Stanford	11/28/2002		
	,								
						<u> </u>			
									I

Examiner	Date		 
Signature	Consider	red	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation, if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.



			Complete if Known	
		Application Number		
INFOR	MATION DISCLOSURE	Filing Date	12/03/2002	
STATE	MENT BY APPLICANT	First Named Inventor	LAURENCE GOUX-CAPES	
		Group Art Unit	N/A	
(use as many sheets as	necessary)	Examiner Name	N/A	
Sheet	2 of 2	Attorney Docket Number	CML00690CR	

Sheet		Automot Bother Humber	_
		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	<u>-</u>	Guo, Z.; Sadler, P.; Tsang, S.; "IMMOBILIZATION AND VISUALIZATION OF DNA AND PROTEINS ON CARBON NANOTUBES" Advanced Materials vol 10. no. 9 1998 701-703	
		Dwyer, C.; Guthold, M.; Falvo, M. Washburn, S.; Superfine, R.; Erie, D. "DNA-FUNCTIONALIZED SINGLE-WALLED CARBON NANOTUBES" Nanotechnology no. 13, September 6, 2002; pgs 601-604	
		Balavoine, F.; Schultz, P. Richard, C.; Mallouh, V.; Ebbesen, T. Mioskowski, C. "HELICAL CRYSTALLIZATION OF PROTEINS ON CARBON NANOTUBES: A FIRST STEP TOWARDS THE DEVELOPMENT OF NEW BIOSENSORS" Angew. Chem. Int. Ed. 1999, 38, No. 13/14	
Examiner	T	Date	

Examiner
Signature

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation, if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.